What are the latest figures on the coagulation factor deficiency market’s size and projected CAGR?
The coagulation factor deficiency market size has grown strongly in recent years. It will grow from $4.58 billion in 2024 to $4.94 billion in 2025 at a compound annual growth rate (CAGR) of 8.0%. The growth in the historic period can be attributed to the increasing prevalence of hemophilia, the introduction of recombinant factors, growing awareness of coagulation disorders, a rise in diagnostic capabilities, government support for rare diseases, the emergence of prophylactic therapies, the expansion of patient registries, and increasing investment in biotechnology.
The coagulation factor deficiency market size is expected to see strong growth in the next few years. It will grow to $6.64 billion in 2029 at a compound annual growth rate (CAGR) of 7.7%. The growth in the forecast period can be attributed to the growing adoption of gene therapies, increasing focus on personalized medicine, rising prevalence of coagulation disorders, expanding access in emerging markets, and integration of digital health solutions and continuous innovation in biomanufacturing technologies. Major trends in the forecast period include gene editing technologies such as CRISPR, development of long-acting recombinant factors, advancements in gene therapy delivery systems, wearable coagulation monitoring devices, artificial intelligence for treatment optimization, point-of-care diagnostic tools, nanoparticle-based drug delivery, plasma-free recombinant product development, biosimilar innovation, and integration of precision medicine approaches.
Get Your Free Sample of The Global Coagulation Factor Deficiency Market Report:
https://www.thebusinessresearchcompany.com/sample.aspx?id=21152&type=smp
Which Market drivers have played a significant role in driving the coagulation factor deficiency market?
The increasing incidences of blood-related disorders are expected to propel the growth of the coagulation factor deficiency market going forward. Blood-related disorders refer to a group of conditions that affect the production, function, or composition of blood cells, platelets, or plasma, leading to issues such as anemia, clotting problems, or immune system deficiencies. Blood-related disorders are increasing due to factors such as aging populations, genetic predispositions, rising awareness, environmental factors, lifestyle changes, and the growing burden of chronic diseases and advancements in diagnostic technologies that allow for earlier detection. Coagulation factor deficiency helps manage blood-related disorders by providing the essential clotting factors needed to prevent or control excessive bleeding in conditions like hemophilia, where the body’s natural ability to form blood clots is impaired. For instance, in September 2024, according to the Leukemia and Lymphoma Society, a US-based professional organization company Every 3 minutes, one person in the US is diagnosed with leukemia, lymphoma, or myeloma. In 2024, an estimated 187,740 individuals face these cancers, representing 9.4% of the expected 2,001,140 new cancer cases in the US. Moreover, in May 2024, according to the National Health Service (NHS) England, a UK-based government-funded healthcare system, in England, approximately 17,000 people are living with sickle cell disease, an inherited blood disorder, with around 250 new cases diagnosed annually. Therefore, the increasing incidences of blood-related disorders are driving the growth of the coagulation factor deficiency market.
What are the key segments within the coagulation factor deficiency market?
The coagulation factor deficiency market covered in this report is segmented –
1) By Product: Recombinant Coagulation Factor Concentrates, Plasma-derived Coagulation Factor Concentrates, Biologics, Desmopressin, Other Product Types
2) By Deficiency Type: Haemophilia A, Hemophilia B, Von Willebrand Disease, Factor XI Deficiency, Factor XIII Deficiency, Other Treatment Types
3) By End Users: Hospitals, Clinics, Home Care, Other End Users
Subsegments:
1) By Recombinant Coagulation Factor Concentrates: Recombinant Factor VIII, Recombinant Factor IX, Recombinant Factor VIIa, Other Recombinant Factors
2) By Plasma-derived Coagulation Factor Concentrates: Plasma-derived Factor VIII, Plasma-derived Factor IX, Plasma-derived Factor VII, Other Plasma-derived Factors
3) By Biologics: Monoclonal Antibodies, Gene Therapy Products
4) By Desmopressin: Intravenous Desmopressin, Intranasal Desmopressin
5) By Other Product Types: Fresh Frozen Plasma (FFP), Prothrombin Complex Concentrates (PCC)
Order your report now for swift delivery
https://www.thebusinessresearchcompany.com/report/coagulation-factor-deficiency-global-market-report
Which key players are shaping the coagulation factor deficiency market?
Major companies operating in the coagulation factor deficiency market are Pfizer Inc., F Hoffmann-La Roche Ltd., Bayer HealthCare Pharmaceuticals, Sanofi Genzyme, Novo Nordisk A/S, Baxter International Inc., CSL Behring LLC, Grifols S.A., Octapharma AG, Takeda Pharmaceutical Company Limited, Swedish Orphan Biovitrum AB, GC Biopharma Co. Ltd., Alnylam Pharmaceuticals Inc., Opko Health Inc., Kedrion Biopharma Inc., Shanghai RAAS Blood Products Co. Ltd., LFB S.A., Biotest AG, Spark Therapeutics Inc., Biogen Inc., Sangamo Therapeutics Inc., Centessa Pharmaceuticals Inc.
Which transformative trends will shape the coagulation factor deficiency market landscape?
Major companies operating in the coagulation factor deficiency market are focusing on developing innovative therapies, such as one-time gene therapy, to provide long-term or potentially curative solutions for patients with bleeding disorders like hemophilia, reducing the need for lifelong infusions of clotting factors. One-time gene therapy refers to a medical treatment that involves the introduction or alteration of genetic material within a patient’s cells to treat or cure a disease, with the aim of providing long-lasting or permanent therapeutic effects after a single administration. For instance, in April 2024, Pfizer Inc., a US-based pharmaceutical and biotechnology company, announced that the U.S. Food and Drug Administration (FDA) has approved BEQVEZ (fidanacogene elaparvovec-dzkt) for the treatment of adults with moderate to severe hemophilia B who currently use factor IX (FIX) prophylaxis therapy. It is a one-time adeno-associated virus (AAV)-based gene therapy designed to introduce in the transduced cells a functional copy of the FIX gene encoding a high-activity FIX variant. For patients with hemophilia B, the gene therapy enables them to produce FIX themselves via this one-time treatment rather than having to receive frequent infusions of FIX.
How do regional factors impact the coagulation factor deficiency market, and which region is the largest contributor?
North America was the largest region in the coagulation factor deficiency market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the coagulation factor deficiency market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
What Does The Coagulation Factor Deficiency Market Report 2025 Offer?
The coagulation factor deficiency market research report from The Business Research Company offers global market size, growth rate, regional shares, competitor analysis, detailed segments, trends, and opportunities.
Coagulation factor deficiency refers to a condition where the body lacks one or more clotting factors necessary for blood coagulation, leading to prolonged bleeding or difficulty in stopping bleeding. These deficiencies are treated with clotting factor concentrates and other therapies, which are used to manage and prevent bleeding episodes in patients with conditions like hemophilia.
Purchase the exclusive report now to unlock valuable market insights:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=21152
With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead.
Our flagship product, the Global Market Model, is a premier market intelligence platform delivering comprehensive and updated forecasts to support informed decision-making.
Contact Us:
The Business Research Company
Europe: +44 207 1930 708
Asia: +91 88972 63534
Americas: +1 315 623 0293
Email: info@tbrc.info
Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
Twitter: https://twitter.com/tbrc_info
Facebook: https://www.facebook.com/TheBusinessResearchCompany
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Blog: https://blog.tbrc.info/
Healthcare Blog: https://healthcareresearchreports.com/
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
